Hims & Hers is a Strong Buy, as shares appear historically cheap due to temporary margin compression and regulatory concerns. HIMS's recurring revenue model, 70%+ gross margins, and rapid subscriber ...
NEW YORK, March 2 (Reuters) - Telehealth company Hims & Hers Health (HIMS.N), opens new tab, known for its weight-loss drug business, is promising it can diversify away from its reliance on compounded ...
GLP-1 seller Hims & Hers Health (NYSE: HIMS) has seen significant volatility in its stock price as of late. Notably, despite seeing a 41% single-day surge in early March, HIMS remains down nearly 10% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results